Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3.

Molecular neurodegeneration - 4 Nov 2019

Li Quan-Fu, Dong Yi, Yang Lu, Xie Juan-Juan, Ma Yin, Du Yi-Chu, Cheng Hao-Ling, Ni Wang, Wu Zhi-Ying

Abstract excerpt

BACKGROUND: Spinocerebellar ataxia type 3 (SCA3) is the most common subtype of autosomal dominantly inherited spinocerebellar ataxias (SCAs). No validated blood biomarker is available to assess either disease progression or therapeutic response. Neurofilament light chain (NfL) was recently proposed as a serum biomarker for many neurodegenerative disorders. The present study investigated whether NfL was a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Brain Stem
Share to Cerebellar Ataxia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Intermediate Filaments

Share to Machado-Joseph Disease

Share to Neurofilament Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 31684998
DOI: 10.1186/s13024-019-0338-0
PMCID: PMC6829913

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3.PMID 31684998Read ↗

Association of serum neurofilament light and disease severity in patients with spinocerebellar ataxia type 3.Semantic proximity Read ↗

Plasma neurofilament light chain predicts cerebellar atrophy and clinical progression in spinocerebellar ataxiaSemantic proximity Read ↗

Association of the Level of Neurofilament Light With Disease Severity in Patients With Spinocerebellar Ataxia Type 2Semantic proximity Read ↗

Tau and neurofilament light‐chain as fluid biomarkers in spinocerebellar ataxia type 3Semantic proximity Read ↗

Blood Neurofilament Light Chain in Genetic Ataxia: A Meta‐AnalysisSemantic proximity Read ↗

Association between with Serum neurofilament light and neurochemistry deficits in patients with spinocerebellar ataxia type 3Semantic proximity Read ↗

Stage-dependent biomarker changes in spinocerebellar ataxia type 3Semantic proximity Read ↗

Neurofilament light chain: a biomarker at the crossroads of clarity and confusion for gene-directed therapiesSemantic proximity Read ↗

Serum Neurofilament Light in Patients with Frontotemporal Dementia Caused by CHMP2B Mutation.Semantic proximity Read ↗

Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s diseaseSemantic proximity Read ↗

Emerging biomarkers in amyotrophic lateral sclerosis: from pathogenesis to clinical applicationsSemantic proximity Read ↗

Molecular Biomarkers in Neurological Diseases: Advances in Diagnosis and PrognosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.